<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370526</url>
  </required_header>
  <id_info>
    <org_study_id>PM-CLIN 008</org_study_id>
    <nct_id>NCT00370526</nct_id>
  </id_info>
  <brief_title>HEAL-HF: A Cardiac Resynchronization Therapy (CRT) Outcomes Study</brief_title>
  <official_title>HEmodynamic Assessment of Optimal Left Heart Lead Placement for Heart Failure Enabled by Magnetic Navigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stereotaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stereotaxis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The literature shows that approximately 40% of individuals who receive a cardiac
      resynchronization therapy (CRT) device for symptomatic congestive heart failure (CHF) do not
      have a clinical benefit from the device. The HEAL-HF protocol will compare the outcomes of
      conventionally placed CRT devices with magnetically placed CRT devices by assessing
      hemodynamic parameters during the magnetic placement of the left ventricular (LV) lead.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline information will be obtained including QoL, 6-minute walk, and echo measurements.
      The patient will be randomized to receive a conventionally-placed LV lead or randomized to
      receive a magnetically-placed LV lead. The magnetic group will have acute hemodynamics
      assessed during the procedure to evaluate the best response of the left ventricle during
      pacing. Patients will be followed for 6 months with a re-evaluation of the baseline tests to
      assess the change in HF symptoms. Adverse events will also be recorded during the follow-up
      period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in end systolic volume (ESV)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Class</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac-related mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF-related hospitalizations</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic cardiomyopathy

          -  Ejection Fraction (EF) &lt;= 35%

          -  QRS duration &gt;= 120 msec

          -  Standard heart failure (HF) oral medications for at least 1 month

          -  Evidence of mechanical dyssynchrony

          -  NYHA Class III or IV

        Exclusion Criteria:

          -  Persistent or chronic atrial fibrillation (AF)

          -  Hemodynamically unstable or uncontrolled arrhythmias

          -  Unstable angina

          -  Aortic valve (AV) insufficiency or stenosis

          -  Mitral valve (MV) regurgitation &gt; 2+

          -  Active infection

          -  Contraindications for heparin

          -  Dependence on atrial pacing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Pappone, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Raffaele University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northeast Georgia Heart Center, PC</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Virginia - Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele University Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2006</study_first_submitted>
  <study_first_submitted_qc>August 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2006</study_first_posted>
  <last_update_submitted>January 2, 2008</last_update_submitted>
  <last_update_submitted_qc>January 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Mark Jacob, Senrior Manager of Clinical Affairs</name_title>
    <organization>Stereotaxis, Inc.</organization>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>resynchronization</keyword>
  <keyword>CRT</keyword>
  <keyword>Bi-V pacemaker</keyword>
  <keyword>LV lead placement</keyword>
  <keyword>hemodynamic assessment</keyword>
  <keyword>CRT Outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

